J&J: halts study on a vaccine against E. coli
(CercleFinance.com) - Johnson & Johnson announces that the Phase 3 E.
mbrace study of its investigational vaccine against extra-intestinal pathogenic E. coli (ExPEC), conducted with Sanofi, has been discontinued.
An independent data monitoring committee concluded that the vaccine was not sufficiently effective in preventing invasive E. coli disease (IED) compared with placebo.
No safety signals were identified.
Johnson & Johnson will follow up participants and share further analyses with the scientific community.
Copyright (c) 2025 CercleFinance.com. All rights reserved.
mbrace study of its investigational vaccine against extra-intestinal pathogenic E. coli (ExPEC), conducted with Sanofi, has been discontinued.
An independent data monitoring committee concluded that the vaccine was not sufficiently effective in preventing invasive E. coli disease (IED) compared with placebo.
No safety signals were identified.
Johnson & Johnson will follow up participants and share further analyses with the scientific community.
Copyright (c) 2025 CercleFinance.com. All rights reserved.